Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Renal Cell 3Neoplasm Metastasis 2Kidney Neoplasms 2Urogenital Neoplasms 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1PRETEXT I Hepatoblastoma 1Lymphoma, Mantle-Cell 1Lymphoma 1Breast Neoplasms 1

Interventions

Radiotherapy 10Vincristine 9Dactinomycin 8Cyclophosphamide 8Radiation 6Ifosfamide 6Doxorubicin 5Irinotecan 4Filgrastim 4Etoposide 4Vinorelbine 3sargramostim 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Granulocyte Colony-Stimulating Factor 2Biopsy 2trofosfamide 1trioctyl phosphine oxide 1temsirolimus 1pegfilgrastim 1etoposide phosphate 1X-Rays 1Topotecan 1Surgical Procedures, Operative 1Spinal Puncture 1Sirolimus 1Sentinel Lymph Node Biopsy 1Phantoms, Imaging 1Idarubicin 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Rhabdomyosarcoma × temsirolimus × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡